Redefining the role of biomarkers in heart failure trials: expert consensus document

Frank Kramer*, Hani N. Sabbah, James J. Januzzi, Faiez Zannad, J. Peter van Tintelen, Erik B. Schelbert, Raymond J. Kim, Hendrik Milting, Richardus Vonk, Brien Neudeck, Richard Clark, Klaus Witte, Wilfried Dinh, Burkert Pieske, Javed Butler, Mihai Gheorghiade

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Heart failure is a growing cardiovascular disease with significant epidemiological, clinical, and societal implications and represents a high unmet need. Strong efforts are currently underway by academic and industrial researchers to develop novel treatments for heart failure. Biomarkers play an important role in patient selection and monitoring in drug trials and in clinical management. The present review gives an overview of the role of available molecular, imaging, and device-derived digital biomarkers in heart failure drug development and highlights capabilities and limitations of biomarker use in this context.

Original languageEnglish (US)
Pages (from-to)263-277
Number of pages15
JournalHeart Failure Reviews
Issue number3
StatePublished - May 1 2017


  • Biomarker
  • Clinical trial
  • Drug development
  • Heart failure
  • Imaging
  • Medical device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Redefining the role of biomarkers in heart failure trials: expert consensus document'. Together they form a unique fingerprint.

Cite this